Lupin surges as its arm acquires Renascience Pharma in United Kingdom
Lupin is currently trading at Rs. 2135.20, up by 125.80 points or 6.26% from its previous closing of Rs. 2009.40 on the BSE.
The scrip opened at Rs. 2071.05 and has touched a high and low of Rs. 2144.30 and Rs. 2071.05 respectively. So far 16188 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1493.75 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 2144.30 and Rs. 1938.55 respectively. The current market cap of the company is Rs. 91742.18 crore.
The promoters holding in the company stood at 46.95%, while Institutions and Non-Institutions held 46.79% and 6.26% respectively.
Lupin’s wholly owned subsidiary -- Lupin Healthcare (UK) has acquired Renascience Pharma (Renascience), a United Kingdom (UK)-based pharmaceutical company and sole supplier of 4 specialty products targeting unmet medical needs in the UK.
With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary. The portfolio includes branded injectable cephalosporines for infectious diseases, a topical treatment for ear pain and a branded quinazoline-like diuretic for cardiovascular and renal indications.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
